Similar articles

• Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?

  Buikhuisen WA, Burgers JA, Vincent AD, Schellens JH, Beijnen JH, Smit EF, Joerger M. Buikhuisen WA, et al. J Clin Oncol. 2010 Sep 20;28(27):e482-3; author reply e484. doi: 10.1200/JCO.2010.29.1559. Epub 2010 Jul 6. J Clin Oncol. 2010. PMID: 20606096 No abstract available.
• Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect?

  Besse B, Le Chevalier T. Besse B, et al. J Clin Oncol. 2008 Nov 1;26(31):5014-7. doi: 10.1200/JCO.2008.18.1081. Epub 2008 Sep 22. J Clin Oncol. 2008. PMID: 18809602 No abstract available.
• New agents in advanced non-small-cell lung cancer treatment.

  Ricciardi S, de Marinis F. Ricciardi S, et al. Oncology. 2009;77 Suppl 1:103-12. doi: 10.1159/000258502. Epub 2010 Feb 2. Oncology. 2009. PMID: 20130438 Review.
• Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

  Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, Paschold E, Iannotti NO, Dakhil S, Gorton S, Pautret V, Weber MR, Woytowitz D. Lynch TJ, et al. J Clin Oncol. 2010 Feb 20;28(6):911-7. doi: 10.1200/JCO.2009.21.9618. Epub 2010 Jan 25. J Clin Oncol. 2010. PMID: 20100966 Clinical Trial.
• [Combination chemotherapy for treatment of metastasing non-small-cell lung carcinoma. Monotherapy of combinations of two or three agents--a survey of a Cochrane review].

  Mellemgaard A, Pappot H. Mellemgaard A, et al. Ugeskr Laeger. 2009 Jun 15;171(25):2084-7. Ugeskr Laeger. 2009. PMID: 19671386 Review. Danish. No abstract available.